Administration of IL-1Ra chitosan nanoparticles enhances the therapeutic efficacy of mesenchymal stem cell transplantation in acute liver failure

Arch Med Res. 2013 Jul;44(5):370-9. doi: 10.1016/j.arcmed.2013.06.004. Epub 2013 Jul 31.

Abstract

Background and aims: To investigate the synergistic effect of IL-1Ra administration and stem cell transplantation in swine suffering from acute liver failure (ALF), to elucidate the mechanism of IL-1Ra activity and to demonstrate mesenchymal stem cell (MSC) transplantation as a potential treatment for ALF.

Methods: Thirty-five Chinese experimental mini-swine were divided into five groups randomly. Group A (n = 7) is the control group and all swine were injected with saline via portal veins. Group B (n = 7) received IL-1Ra via ear veins 6 h before receiving saline. Group C (n = 7) received MSC transplantation and all swine were injected with 8 × 10⁷ MSCs via portal veins. Group D (n = 7) swine were treated with a combination of IL-1Ra and MSC transplantation E (n = 7) also received a combined treatment of both IL-1Ra and bone marrow (BM-MSC) transplantation, except that the IL-1Ra was in the form of chitosan nanoparticles. Liver function, level of cytokines and liver pathological changes were measured in the following 4 weeks.

Results: IL-1Ra chitosan nanoparticles exhibited controlled-release ability in PBS. Swine in Group E showed a significant improvement in inflammation environment, liver function and hepatocyte proliferation. Levels of hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) in Group E were elevated compared to other groups.

Conclusions: IL-1Ra chitosan nanoparticles showed significant liver targeting ability and controlled-release characteristics. Combined therapy with IL-1Ra chitosan nanoparticles and MCS transplantation exhibits great synergistic effects through paracrine function and suppression of inflammation.

Keywords: Acute liver failure; Cell transplantation; Chitosan nanoparticles; IL-1Ra; Mesenchymal stem cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Chitosan / administration & dosage*
  • Cytokines / metabolism
  • Delayed-Action Preparations
  • Drug Carriers / administration & dosage
  • Drug Synergism
  • Hepatocytes / drug effects
  • Hepatocytes / pathology
  • Interleukin 1 Receptor Antagonist Protein / administration & dosage*
  • Liver Failure, Acute / chemically induced
  • Liver Failure, Acute / pathology
  • Liver Failure, Acute / therapy*
  • Mesenchymal Stem Cell Transplantation / methods*
  • Mesenchymal Stem Cells / metabolism
  • Nanoparticles / administration & dosage*
  • Random Allocation
  • Swine

Substances

  • Cytokines
  • Delayed-Action Preparations
  • Drug Carriers
  • Interleukin 1 Receptor Antagonist Protein
  • Chitosan